Clinical trial
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who…
NCT00362700 · Bukwang Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00362700 |
|---|---|
| Title | Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201 |
| Official title | An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201 |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Clevudine |
| Enrollment | 33 |
| Start date | Jul 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Aug 10, 2006 |
| Last update posted | Feb 1, 2017 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: